Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04090346 · ClinicalTrials.gov registry record · Phase 4

Fecal Microbiota Transplant

A Phase 4 study, sponsored by Methodist Health System.

Completed
Registry status
Phase 4
Development phase
24
Enrollment target

NCT04090346: Completed Phase 4 study, sponsored by Methodist Health System.

NCT04090346 is a Phase 4 study that has completed, run by Methodist Health System. The registered enrollment target is 24 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04090346, a Phase 4 study, has completed, sponsored by Methodist Health System.

COMPLETED
Registry status
Phase 4
Development phase
24 participants
Enrollment target

Study Summary

The study will provide data to show the effectiveness of Fecal Microbiota Transplant in patients with recurrent Clostridium difficile infection. Fecal Microbiota Transplant (FMT) is a procedure in which healthy colon contents of a carefully screened donor is inserted into the colon of a compromised patient. FMT is a procedure to replace beneficial bacteria that has been killed or suppressed, most commonly by use of antibiotics. Currently it is utilized as an experimental treatment for Clostridium difficile infection (CDI). This procedure is predicted to reduce the cost both financially and physically for the CDI patient and facility.

Primary Outcome

date of treatment

Interventions

  • DRUG Fecal Microbiota Transplant

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2018-06-05
Est. Completion 2022-03-30
Phase Phase 4
Methodist Health System

125 total trials

What the finished NCT04090346 record still lists

NCT04090346 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 1 intervention - of which Fecal Microbiota Transplant is the first listed.

NCT04090346 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04090346 about?

NCT04090346 is a clinical study titled "Fecal Microbiota Transplant". The study will provide data to show the effectiveness of Fecal Microbiota Transplant in patients with recurrent Clostridium difficile infection. Fecal Microbiota Transplant (FMT) is a procedure in which healthy colon contents of a carefully screened donor is inserted into the colon of a compromised...

What is the current status of trial NCT04090346?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2018-06-05. Estimated completion is 2022-03-30.

What interventions are being tested in trial NCT04090346?

The interventions under investigation include: Fecal Microbiota Transplant (DRUG).

Who is sponsoring clinical trial NCT04090346?

This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04090346's enrollment target sits among peer trials

24 1699th of 2000 higher than 276 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04090346, the US trial registry maintained by the National Library of Medicine. NCT04090346 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.